Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

The enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells.

Lewis EM, Wilkinson AS, Jackson JS, Mehra R, Varambally S, Chinnaiyan AM, Wilkinson JC.

J Biol Chem. 2012 Dec 21;287(52):43862-75. doi: 10.1074/jbc.M112.407650. Epub 2012 Nov 1.

2.

Basal metabolic state governs AIF-dependent growth support in pancreatic cancer cells.

Scott AJ, Wilkinson AS, Wilkinson JC.

BMC Cancer. 2016 Apr 23;16:286. doi: 10.1186/s12885-016-2320-3.

3.

Apoptosis-inducing Factor (AIF) and Its Family Member Protein, AMID, Are Rotenone-sensitive NADH:Ubiquinone Oxidoreductases (NDH-2).

Elguindy MM, Nakamaru-Ogiso E.

J Biol Chem. 2015 Aug 21;290(34):20815-26. doi: 10.1074/jbc.M115.641498. Epub 2015 Jun 10.

4.

Finasteride inhibits human prostate cancer cell invasion through MMP2 and MMP9 downregulation.

Moroz A, Delella FK, Almeida R, Lacorte LM, Fávaro WJ, Deffune E, Felisbino SL.

PLoS One. 2013 Dec 30;8(12):e84757. doi: 10.1371/journal.pone.0084757. eCollection 2013.

5.

Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2.

Chen J, Deng F, Singh SV, Wang QJ.

Cancer Res. 2008 May 15;68(10):3844-53. doi: 10.1158/0008-5472.CAN-07-5156.

6.

Nuclear translocation of apoptosis inducing factor is associated with cisplatin induced apoptosis in LNCaP prostate cancer cells.

Zhang W, Zhang C, Narayani N, Du C, Balaji KC.

Cancer Lett. 2007 Sep 18;255(1):127-34. Epub 2007 Jun 7.

PMID:
17560018
7.

AIF downregulation and its interaction with STK3 in renal cell carcinoma.

Xu S, Wu H, Nie H, Yue L, Jiang H, Xiao S, Li Y.

PLoS One. 2014 Jul 3;9(7):e100824. doi: 10.1371/journal.pone.0100824. eCollection 2014.

8.

Hepatocyte growth factor and HER2/neu downregulate expression of apoptosis-inducing factor in non-small cell lung cancer.

Chiang YY, Chow KC, Lin TY, Chiang IP, Fang HY.

Oncol Rep. 2014 Feb;31(2):597-604. doi: 10.3892/or.2013.2867. Epub 2013 Nov 25.

PMID:
24276579
9.

Suppression of telomerase, reexpression of KAI1, and abrogation of tumorigenicity by nerve growth factor in prostate cancer cell lines.

Sigala S, Faraoni I, Botticini D, Paez-Pereda M, Missale C, Bonmassar E, Spano P.

Clin Cancer Res. 1999 May;5(5):1211-8.

10.

14-3-3sigma is down-regulated in human prostate cancer.

Urano T, Takahashi S, Suzuki T, Fujimura T, Fujita M, Kumagai J, Horie-Inoue K, Sasano H, Kitamura T, Ouchi Y, Inoue S.

Biochem Biophys Res Commun. 2004 Jul 2;319(3):795-800.

PMID:
15184053
11.

MicroRNA145 targets BNIP3 and suppresses prostate cancer progression.

Chen X, Gong J, Zeng H, Chen N, Huang R, Huang Y, Nie L, Xu M, Xia J, Zhao F, Meng W, Zhou Q.

Cancer Res. 2010 Apr 1;70(7):2728-38. doi: 10.1158/0008-5472.CAN-09-3718. Epub 2010 Mar 23.

12.

Apoptosis-inducing factor: structure, function, and redox regulation.

Sevrioukova IF.

Antioxid Redox Signal. 2011 Jun 15;14(12):2545-79. doi: 10.1089/ars.2010.3445. Epub 2011 Mar 10. Review.

13.

Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.

Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A.

Cancer J. 2000 Jul-Aug;6(4):220-33.

PMID:
11038142
14.

Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.

Laurenzana A, Balliu M, Cellai C, Romanelli MN, Paoletti F.

PLoS One. 2013;8(3):e58267. doi: 10.1371/journal.pone.0058267. Epub 2013 Mar 4.

15.

Immunohistochemical and mutational analysis of apoptosis-inducing factor (AIF) in colorectal carcinomas.

Jeong EG, Lee JW, Soung YH, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH.

APMIS. 2006 Dec;114(12):867-73.

PMID:
17207087
17.

CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation.

Roca H, Varsos Z, Pienta KJ.

J Biol Chem. 2008 Sep 5;283(36):25057-73. doi: 10.1074/jbc.M801073200. Epub 2008 Jul 8.

18.

The roles of AIF and Endo G in the apoptotic effects of benzyl isothiocyanate on DU 145 human prostate cancer cells via the mitochondrial signaling pathway.

Liu KC, Huang YT, Wu PP, Ji BC, Yang JS, Yang JL, Chiu TH, Chueh FS, Chung JG.

Int J Oncol. 2011 Mar;38(3):787-96. doi: 10.3892/ijo.2010.894. Epub 2010 Dec 30.

PMID:
21206973
19.

Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins.

Tang DG, Li L, Chopra DP, Porter AT.

Cancer Res. 1998 Aug 1;58(15):3466-79. Erratum in: Cancer Res 1998 Nov 15;58(22):5260.

20.

CDK inhibitors induce mitochondria-mediated apoptosis through the activation of polyamine catabolic pathway in LNCaP, DU145 and PC3 prostate cancer cells.

Arisan ED, Obakan P, Coker-Gurkan A, Calcabrini A, Agostinelli E, Unsal NP.

Curr Pharm Des. 2014;20(2):180-8.

PMID:
23701543

Supplemental Content

Support Center